Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations

References

• Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348: 2339–47
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Wong N, Rozen F, Brunet J-S, Narod SA. Survival of patients with breast cancer and BRCA1 mutations. Lancet 1998; 351: 1359–60
   PubMed Web of Science ®Google Scholar
• Verhoog LC, Brekelmans CTM, Seynaeve C, Van den Bosch LMC, Dahmen G, Van Geel AN, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351: 316–21
   PubMed Web of Science ®Google Scholar
• Møller P, Borg Å, Evans DG, Haites N, Reis MM, Vasen H, et al. Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002; 101: 555–9
   PubMed Web of Science ®Google Scholar
• Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, et al. A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004; 6: R8–R17
   PubMed Web of Science ®Google Scholar
• Johannsson OT, Idvall I, Anderson C, Borg Å, Barkardottir RB, Egilsson V, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997; 33: 362–71
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer. Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310–8
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482–5
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418–23
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LJ, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu Proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12
   PubMed Web of Science ®Google Scholar
• Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou J-Y, Yanling M, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridisation: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894–904
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737–44
   PubMed Web of Science ®Google Scholar
• Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001; 7: 1577–81
   PubMed Web of Science ®Google Scholar
• Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, et al. Amplification and overexpression of topoisomerase IIa predict response to anthracycline-based therapy in locally advanced cancer. Clin Cancer Res 2002; 8: 1061–7
   PubMed Web of Science ®Google Scholar
• Park K, Kim J, Lim S, Han S. Topoisomerase II-a and HER2 amplification in breast cancers. Eur J Cancer 2003; 39: 631–4
   PubMed Web of Science ®Google Scholar
• Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994; 303(PT 3)681–95
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zwelling LA, Kawakami Y, An T, Kobayashi K, Herzog C, et al. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 1999; 59: 4618–24
   PubMed Web of Science ®Google Scholar
• Järvinen AHT, Tanner M, Rantanen V, Bärlund M, Borg Å, Grenman S, et al. Amplification and deletion of topoisomerase IIa with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156: 839–47
   PubMed Web of Science ®Google Scholar
• Järvinen TAH, Liu ET. Effects of HER-2/neu on chemosensitivity of tumour cells. Drug Resist Updates 2000; 3: 319–24
   PubMed Web of Science ®Google Scholar
• Bofin AM, Ytterhus B, Hagmar BM. Topoisomerase IIa and HER2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 2003; 14: 314–9
   PubMed Web of Science ®Google Scholar
• Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–10
   PubMed Web of Science ®Google Scholar
• Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, et al. Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57: 233–7
   PubMed Web of Science ®Google Scholar
• Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 2002; 62: 1481–8
   PubMed Web of Science ®Google Scholar
• Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483–90
   PubMed Web of Science ®Google Scholar
• Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive hormone receptor negative breast cancer. J Natl Cancer Inst 1998; 90: 1361–70
   PubMed Web of Science ®Google Scholar
• Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrøm P, et al. Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428–36
   PubMed Web of Science ®Google Scholar
• De Pender AMG, Alers JC, Vissers KJ, de Both NJ, Dinjens WNM, van Dekken H. Evaluation of oncogene amplification in intact and truncated cell nuclei of gastro-esophageal cancer cell lines by DNA in situ hybridisation. Acta Histochem 2001; 103: 127–38
   PubMed Web of Science ®Google Scholar